Soohwan Yum
Busan, 609735, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Minoxidil Induction of VEGF Is Mediated by Inhibition of HIF-Prolyl Hydroxylase.
Journal: International journal of molecular sciences
Published: November 22, 2017
Colon-targeted delivery of piceatannol enhances anti-colitic effects of the natural product: potential molecular mechanisms for therapeutic enhancement.
Journal: Drug design, development and therapy
Published: August 15, 2015
HIF-prolyl hydroxylase is a potential molecular target for esculetin-mediated anti-colitic effects.
Journal: Fitoterapia
Published: January 03, 2015
Lipophilic modification enhances anti-colitic properties of rosmarinic acid by potentiating its HIF-prolyl hydroxylases inhibitory activity.
Journal: European journal of pharmacology
Published: September 11, 2014
N-(2-Mercaptopropionyl)-glycine, a diffusible antioxidant, activates HIF-1 by inhibiting HIF prolyl hydroxylase-2: implication in amelioration of rat colitis by the antioxidant.
Journal: Biochemical and biophysical research communications
Published: December 06, 2013
Colon-targeted celecoxib ameliorates TNBS-induced rat colitis: a potential pharmacologic mechanism and therapeutic advantages.
Journal: European journal of pharmacology
Published: September 18, 2013
Caffeic acid phenethyl ester activation of Nrf2 pathway is enhanced under oxidative state: structural analysis and potential as a pathologically targeted therapeutic agent in treatment of colonic inflammation.
Journal: Free radical biology & medicine
Published: January 18, 2013
Dithiocarbamate chitosan as a potential polymeric matrix for controlled drug release.
Journal: Drug development and industrial pharmacy
Published: January 18, 2013
Piceatannol, a hydroxystilbene natural product, stabilizes HIF-1α protein by inhibiting HIF prolyl hydroxylase.
Journal: European journal of pharmacology
Published: August 17, 2012
Colon-targeted cell-permeable NFκB inhibitory peptide is orally active against experimental colitis.
Colon-targeted cell-permeable NFκB inhibitory peptide is orally active against experimental colitis.
Journal: Molecular pharmaceutics
Published: March 21, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026